Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 6, 2000, Pages 658-666

  Démolis, Jean Louis ^a,b   Kubitza, Dagmar ^a,b   Tennezé, Laurent ^a,b   Funck Brentano, Christian ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE PREDISPOSITION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; EXERCISE TEST; FEMALE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TORSADE DES POINTES;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; FLUOROQUINOLONES; HEART CONDUCTION SYSTEM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PLACEBOS; QUINOLINES; VENTRICULAR FUNCTION;

EID: 0034525584     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.111482     Document Type: Article

References (46)

1. Quinolone activity against anaerobes
2. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes
3. Risks and benefits of antiarrhythmic therapy
4. When is QT prolongation antiarrhythmic and when is it proarrhythmic?
5. Torsade de pointes: Mechanisms and management
6. The dilemma of the prolonged QT interval in early drug studies
7. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management
8. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder
9. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
10. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
11. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart
12. Torsades de pointes occurring in association with terfenadine use
13. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
14. A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes: A case report
15. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature
16. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers
17. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers
18. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic
19. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
20. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by highperformance liquid chromatography with fluorescence detection using on-column focusing
21. The measurement of the QT interval of the electrocardiogram
22. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans
23. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Reevaluation of Bazett's formula
24. Rate-corrected QT interval: Techniques and limitations
25. An analysis of the time-relations of electrocardiograms
26. Die Sytoledauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken
27. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: Emphasis on the cubic root Fridericia's equation
28. QT prolongation and sudden cardiac death in patients with alcoholic liver disease
29. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval
30. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): Case report and review
31. QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion
32. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates
33. QT prolongation and Torsades de Pointes associated with clarithromycin
34. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin
35. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes
36. Toxicity of quinolones
37. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group
38. Torsades de pointe probably related to sparfloxacin
39. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review
40. Sex differences in the evolution of the electrocardiographic QT interval with age
41. Female gender as a risk factor for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence
42. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
43. Absolute bioavailability of moxifloxacin
44. Tolerance to the repolarization effects of rac-sotalol during long-term treatment
45. Metabolism and excretion of moxifloxacin